INTRODUCTION
However, cell lines have potential usefulness, especially from an industrial view point, such as supply, storage, quality control, etc. To compensate for the diminished A bioartificial liver (BAL) support system is curactivity, we used recombinant technology. Glutamine rently expected to be a novel therapeutic device for the synthetase (GS) gene was transfected to human hepaend stage of hepatic failure (2, 3, 8, 11) . BAL treatment toblastoma cell line, HepG2, and GS-HepG2 was estabwill improve a recipient's condition to bridge to a suclished. The ammonia removal activity of GS-HepG2 cessful transplantation and will support the critical stage was approximately 1/7-8 of that of isolated porcine heof the postoperational period. There are mainly two oppatocytes (4), whereas the original HepG2 cells showed tions for cells used in the bioreactor: isolated hepatono ammonia removal activity. In this communication, cytes (2, 3, 8) and lined cells (11). The former, usually we demonstrate the in vivo estimation of bioartificial isolated porcine hepatocytes, are multifunctional and of liver with GS-HepG2 cells using pigs with ischemic high performance, but the functioning time is relatively liver failure and discuss the advantages and prospects of short (approximately up to 10 days), secreted proteins as this cell line as a bioreactor in BAL. well as cell components possess xenoantigenicity, and cell processing such as isolation, inoculation, and culture MATERIALS AND METHODS is considerably laborious. Moreover, risk of xeno-Cells and Culture Condition zoonosis is a current concern from not only a clinical but also from a public standpoint (1, 10) . On the other GS-HepG2 cells were developed and cultured as dehand, while hepatic cell lines are advantageous in supply scribed previously (4). Briefly, the glutamine synthetase and handling procedures, cell lines almost loose their gene from Chinese hamster ovary cells was inserted in original functions (5) and, from functional evaluation, pBR322 plasmid with cytomegarovirus promoter and cell lines are regarded to be unsuitable for BAL (12). and amplification of the GS gene was performed by cul-two hemodialysis consoles, which were tandemly connected. turing cells under the presence of methionine sulfoximine. GS-HepG2 cells thus obtained were cultured in Monitor of Physiological Indices glutamine-free RDF medium containing glutamate and 5% fetal bovine serum in the circulatory flow bioreactor.
Heart rate, arterial and central venous pressure, and intracranial pressure were monitored continuously (Model The initial number of inoculated cells in the bioreactor was 5 × 10 7 cells and cells were grown to 4 × 10 9 cells.
66S, Hewlett Packard, USA). Blood gas, hemoglobin, electrolyte, and laboratory data [glucose, ammonia, ami-The bioreactor was kept at 37°C and fresh medium, air, CO 2 , and oxygen were supplied as described pre-notransferases, coagulation indices (activated clotting time (ACT), hepaplastin test (HPT), activated partial viously (4). thromboplastin test (APTT)] were estimated every 3 h Ischemic Hepatic Failure Model after the completion of ischemic liver failure (9). Termi-Domestic piglets (2.5-3.5 months old), weighing nation of the heartbeat was regarded as the end point of 20-27 kg, were used for in vivo estimation of BAL. The survival. operating procedure of ischemic liver failure and BAL RESULTS treatment was performed as described previously (9).
Ammonia Removal Activity of GS-HepG2 in the Briefly, the piglet was anesthetized and maintained by Various Conditions 0.5-1.5% Isoflurane (Abbott, Illinois, USA) with muscle relaxant (pancuronium bromide, 2 ml/h, IV). Moni-Ammonia removal activity was detectable in not only toring catheters were inserted to the iliac artery and vein normal but also substrate (glutamic acid)-free culture to measure the arterial and central venous pressure. A medium ( Fig. 1 ). Ammonia removal rates were calcudouble lumen catheter was placed in the right jugular lated by the approximation lines to be almost the same vein for blood access of extracorporeal BAL circulation.
in the two conditions (159.3 and 141.7 µmol/L/h, re-To establish a portosystemic shunt, outlet and inlet cathspectively). Reflecting the decrease of ammonia, glutaeters were put in the portal vein and left jugular vein, mine in the culture medium was increased in both condirespectively, and portal blood was bypassed using a centions (data not shown). GS-HepG2 cells also decreased trifugal blood pump (HPM-15, Nikkisou, Tokyo, Japan). ammonia concentration in plasma from a hepatic failure Then the portal vein, hepatic artery, and common bile pig (ammonia concentration 3.0 mmol/L) with the deduct were ligated. Pigs were supplied inorganic salt solution (Sublood B, Fusou Pharmaceuticals, Osaka, Japan) at a rate of 10 ml/kg/h during the operation and, after the operation, the solution was changed to Sublood B containing 5% glucose at a flow rate of 4 ml/kg/h. No vasopressor was used throughout the experiment.
Treatment of BAL and Plasma Exchange and Continuous Hemodiafiltration
Three hours after the completion of total liver ischemia, BAL treatment was started (9). Blood taken from the double lumen catheter in the right jugular vein was led at a rate of 15 ml/min to a plasma exchange column (PP-03, Ube Medical, Tokyo, Japan), using hemodialysis console (JUN-500, Ube Medical, Tokyo, Japan). Separated plasma (3 ml/min) was flown into the circulatory flow bioreactor with or without GS-HepG2 cells (treated group and control group, respectively) and returned to the jugular vein via the double lumen catheter. All extracorporeal space (550 ml) was primed with Sublood B and pigs were transfused with 600 ml of fresh frozen pig plasma from the beginning of the BAL pan and FH-66D CAVH filter, Gambro, Germany) using crease rate of 187.5 µmol/L/h, which was comparable to fulminant hepatic failure. Although the interval of repeated use was 7-14 days in this experiment, the inter-the activity in the culture medium (data not shown).
val can be shortened if other back-up modules are avail-In Vivo Estimation of the Efficacy of GS-HepG2 BAL able.
Using Pigs With Ischemic Liver Failure
GS-HepG2 cells exhibited ammonia removal activity GS-HepG2 cells were grown from 5 × 10 7 to 4 × 10 9 in substrate-depleted condition and porcine plasma from cells during the culture period (109 days). Judging from a pig with ischemic hepatic failure. In hepatic failure the glucose consumption rate, the cells became stationplasma, glutamine concentration was increased, probaary from culture day 60, and the BAL treatment experibly due to systemic tissue damage, and, under such sement was done with the bioreactor four times at this vere condition, GS-HepG2 catalyzed ammonia removal. stage. No bacterial contamination occurred during the GS requires ammonia, glutamic acid, and ATP as subrepeated use of BAL for 6 weeks. After the in vivo treatstrates and cofactors (6). In the substrate-depleted condiment, the cell damage by the treatment was likely to be tion, perhaps GS catalyzed the reaction with the intracelinsignificant because ammonia removal activity was not lular pool of the substrates, which had been supplied changed before and after the experiment (data not during normal culture medium. The reaction cofactor, shown).
ATP, was likely to be produced by the cell itself. Be-Survival times of the pigs treated with cell-free BAL, cause ammonia removal activity under various circum-GS-HepG2 BAL, and PE and CHDF were 13.8 ± 5.4 stances was almost the same, GS used the intracellular h (n = 6), 18.8 ± 6.1 h (n = 6), and 10.7 ± 4.1 h (n = 6), pool, preferably to substances in the outside medium or respectively ( Table 1) . Although there was no statistical plasma. significance among these three groups, the mean sur-Using GS-HepG2 cells, the BAL treatment prolonged vival time of the GS-HepG2 BAL-treated group was the mean survival time compared with that of cell-free longest. Increase of blood ammonia tended to be lower BAL-treated and PE and CHDF-treated groups, although in GS-HepG2 BAL-treated group than in cell-free BALthe data were not statistically significant. At present, we and PE and CHDF-treated groups from 15 h after the have no clear explanation about the prolongation. Howhepatic ischemia ( Fig. 2A) . Physiological data also indiever, besides survival time, other vital signs (e.g., body cated improvement of coagulation indices, such as ACT, movement) seemed to be improved. One possible reason HPT, and APTT ( Fig. 2B, C, D) . ACT and APTT were may be removal of toxic cytokines as reported prekept in the physiological range during the experiment viously (4). Unexpectedly, blood coagulation indices (Fig. 2B, D) .
were improved in the GS-HepG2 BAL group. Because only a small amount of plasma protein was produced by DISCUSSION GS-HepG2 cells (data not shown), this effect may be Development of BAL is now entering clinical trials due to the suppression of consumption of coagulation (3,8,11). Except for the C3A/HepG2 cell line (11), most factors by the contact of plasma with GS-HepG2. Alresearchers use porcine hepatocytes (2, 3, 8) . Although though the mechanism remains to be clarified, the imporcine hepatocytes possess efficient physiological funcprovement of the indices is correlated with the prolongations, isolated hepatocytes survive for 1 week at most. tion of survival time because coagulation disorder is one Moreover, recent reports pointed out the risk of porcine of main causes of death in fulminant hepatic failure. endogenous retroviral infection (1, 10) . On the other Isolated porcine hepatocytes have been recognized as hand, immortalized cell lines have powerful growth acmost suitable for bioreactor cells in BAL. As shown in tivity and, for instance, some cell lines can be main- Table 2 , isolated hepatocytes exhibit highly differentitained under serum-free medium. This growth ability ated functions, and recent development of culture mawill provide the possibility of repeated use of the biorechinery and cell matrix actualizes equivalent performance to physiological activities (7,13). However, the actor after the exposure of plasma from a patient with 
